Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Sector:
Consumer Services
Industry:
Other Consumer Services
Employees:
Frequently Asked Questions
What is Market Cap of Marker Therapeutics, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Marker Therapeutics, Inc. market cap is $347.5M.
What is the 52-week high for Marker Therapeutics, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Marker Therapeutics, Inc. 52 week high is $10.92 as of September 07, 2025.
What is the 52-week low for Marker Therapeutics, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Marker Therapeutics, Inc. 52 week low is $4.18 as of September 07, 2025.
What is Marker Therapeutics, Inc. stock price today?
Marker Therapeutics, Inc. stock price today is $7.94.
What was Marker Therapeutics, Inc. stock price yesterday?
Marker Therapeutics, Inc. stock price yesterday was $7.69.
What is the PE ratio of Marker Therapeutics, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Marker Therapeutics, Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of Marker Therapeutics, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Marker Therapeutics, Inc. P/B ratio is 6.2488.
What is Marker Therapeutics, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Marker Therapeutics, Inc.'s EBITDA is N/A.
What is the 50-day moving average of Marker Therapeutics, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Marker Therapeutics, Inc. 50-day moving average is $5.81.
How many employess does Marker Therapeutics, Inc. has?
